| Autor: |
Ramazanov GR; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Kokov LS; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Shamalov NA; Federal Center for Brain and Neurotechnologies, Moscow, Russia., Kovaleva EA; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Klychnikova EV; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Akhmatkhanova LK; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Cheboksarov DV; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Khamidova LT; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Muslimov RS; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Rybalko NV; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia., Petrikov SS; Sklifosovsky Clinical and Research Institute for Emergency Medicine, Moscow, Russia. |
| Abstrakt: |
Currently, five oral anticoagulants have been shown to be effective in preventing recurrent ischemic stroke and/or systemic embolism in patients with non-valvular atrial fibrillation. However, 1.1-2.2% of patients taking oral anticoagulants develop ischemic strokes. The use of oral anticoagulants limits the possibility of systemic thrombolytic therapy, as this is associated with an increased risk of symptomatic hemorrhagic transformation. The exception is cases when, with the help of a specific antagonist, it is possible to neutralize the effect of the anticoagulant in the shortest possible time and achieve normocoagulation. Currently, the Russian Federation allows two drugs for systemic thrombolytic therapy in patients with ischemic stroke in the «therapeutic window» up to 4.5 hours from the onset of the disease - recombinant tissue plasminogen activator and non-immunogenic staphylokinase, which showed no less efficacy and safety in the FRIDA study compared to recombinant tissue plasminogen activator. This article describes a clinical case of the first systemic thrombolytic therapy with a non-immunogenic staphylokinase after the use of idarucizumab in a patient taking dabigatran etexilate, followed by thrombectomy. |
